Neal D. Shore, MD, on a Possible New Standard of Care in Oral Therapy for Advanced Prostate Cancer

Posted: Wednesday, June 24, 2020

Neal D. Shore, MD, of the Carolina Urologic Research Center, discusses study results from the HERO trial, which support the use of relugolix vs leuprolide. He talks about the issues that will need to be addressed before this oral GnRH receptor antagonist is considered the new standard of care.